Characteristics of transplant recipients and donors, n = 953
. | African American . | Native American . | Asian . | White . | Hispanic . | Other/unknown . | Combined . |
|---|---|---|---|---|---|---|---|
| No. | 17 | 19 | 24 | 814 | 46 | 33 | 953 |
| Age, y, median (range) | 36 (4-58) | 38 (1-68) | 42 (8-60) | 39 (16-60) | 37 (9-57) | 36 (3-65) | 38 (1-68) |
| Transplantation year, no. (%) | |||||||
| 1981-1991 | 6 (35) | 5 (28) | 6 (25) | 338 (42) | 9 (20) | 10 (30) | 374 (39) |
| 1992-2000 | 11 (65) | 14 (74) | 18 (75) | 476 (58) | 37 (80) | 23 (70) | 579 (61) |
| Sex, patient/donor, no. (%) | |||||||
| Male/male | 4 (24) | 11 (58) | 7 (29) | 268 (33) | 19 (41) | 13 (29) | 322 (34) |
| Male/female | 6 (35) | 4 (21) | 7 (29) | 199 (24) | 9 (20) | 10 (30) | 235 (25) |
| Female/male | 5 (29) | 1 (5) | 5 (21) | 160 (20) | 9 (20) | 2 (6) | 182 (19) |
| Female/female | 2 (12) | 3 (16) | 5 (21) | 187 (23) | 9 (20) | 8 (24) | 214 (22) |
| Total body irradiation, no. (%) | |||||||
| Yes | 9 (53) | 10 (53) | 16 (67) | 361 (44) | 25 (54) | 16 (48) | 438 (46) |
| No | 8 (47) | 9 (47) | 8 (33) | 453 (56) | 21 (46) | 17 (52) | 515 (54) |
| Disease group, no. (%) | |||||||
| Nonmalignant disease* | 2 (12) | 4 (21) | 5 (21) | 137 (17) | 12 (26) | 7 (21) | 167 (18) |
| Low-risk malignance† | 8 (47) | 8 (42) | 14 (58) | 407 (50) | 24 (52) | 13 (39) | 474 (50) |
| High-risk malignance‡ | 7 (41) | 7 (37) | 5 (21) | 270 (33) | 10 (22) | 13 (39) | 312 (33) |
| Cumulative incidence, % | |||||||
| Acute GVHD§ | 18 | 26 | 8 | 19 | 11 | 15 | 19 |
| Chronic GVHD∥ | 41 | 53 | 42 | 41 | 35 | 27 | 40 |
| Nonrelapse mortality∥ | 24 | 37 | 21 | 25 | 28 | 21 | 25 |
| Overall survival∥ | 41 | 58 | 71 | 57 | 56 | 61 | 57 |
. | African American . | Native American . | Asian . | White . | Hispanic . | Other/unknown . | Combined . |
|---|---|---|---|---|---|---|---|
| No. | 17 | 19 | 24 | 814 | 46 | 33 | 953 |
| Age, y, median (range) | 36 (4-58) | 38 (1-68) | 42 (8-60) | 39 (16-60) | 37 (9-57) | 36 (3-65) | 38 (1-68) |
| Transplantation year, no. (%) | |||||||
| 1981-1991 | 6 (35) | 5 (28) | 6 (25) | 338 (42) | 9 (20) | 10 (30) | 374 (39) |
| 1992-2000 | 11 (65) | 14 (74) | 18 (75) | 476 (58) | 37 (80) | 23 (70) | 579 (61) |
| Sex, patient/donor, no. (%) | |||||||
| Male/male | 4 (24) | 11 (58) | 7 (29) | 268 (33) | 19 (41) | 13 (29) | 322 (34) |
| Male/female | 6 (35) | 4 (21) | 7 (29) | 199 (24) | 9 (20) | 10 (30) | 235 (25) |
| Female/male | 5 (29) | 1 (5) | 5 (21) | 160 (20) | 9 (20) | 2 (6) | 182 (19) |
| Female/female | 2 (12) | 3 (16) | 5 (21) | 187 (23) | 9 (20) | 8 (24) | 214 (22) |
| Total body irradiation, no. (%) | |||||||
| Yes | 9 (53) | 10 (53) | 16 (67) | 361 (44) | 25 (54) | 16 (48) | 438 (46) |
| No | 8 (47) | 9 (47) | 8 (33) | 453 (56) | 21 (46) | 17 (52) | 515 (54) |
| Disease group, no. (%) | |||||||
| Nonmalignant disease* | 2 (12) | 4 (21) | 5 (21) | 137 (17) | 12 (26) | 7 (21) | 167 (18) |
| Low-risk malignance† | 8 (47) | 8 (42) | 14 (58) | 407 (50) | 24 (52) | 13 (39) | 474 (50) |
| High-risk malignance‡ | 7 (41) | 7 (37) | 5 (21) | 270 (33) | 10 (22) | 13 (39) | 312 (33) |
| Cumulative incidence, % | |||||||
| Acute GVHD§ | 18 | 26 | 8 | 19 | 11 | 15 | 19 |
| Chronic GVHD∥ | 41 | 53 | 42 | 41 | 35 | 27 | 40 |
| Nonrelapse mortality∥ | 24 | 37 | 21 | 25 | 28 | 21 | 25 |
| Overall survival∥ | 41 | 58 | 71 | 57 | 56 | 61 | 57 |
Patients received a myeloablative hematopoietic cell transplant from an HLA genetically identical sibling donor. This population included 33 patients of other or unknown origin.
Nonmalignant disease includes aplastic anemia, myelodysplastic syndrome, and paroxysmal nocturnal hematuria
Low-risk malignancy includes acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), or non-Hodgkin lymphoma (NHL) in remission and chronic myelogenous leukemia (CML) in chronic phase
High-risk malignancy includes ALL, AML, chronic lymphocytic leukemia, or NHL in relapse, CML in other than chronic phase, multiple myeloma, and Hodgkin disease
Cumulative incidence rates of grades III-IV acute GVHD at day 100
Cumulative incidence rates of chronic extensive GVHD, nonrelapse mortality, and survival at 3 years